F., Mandell, G
Both medications maintain flat monthly pricing regardless of dose escalation
Consistency, sleep, and overall diet strongly influence results
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%
Alexander GC, Emerson S, Kesselheim AS (2021) Evaluation of Aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility
Dosing frequency GLP-1s vary in their dosing frequency, which can significantly impact patient adherence and preference: Twice-daily: Exenatide (Byetta) Once-daily: Liraglutide (Victoza, Saxenda), Semaglutide tablets (Rybelsus) Once-weekly: Semaglutide (Ozempic, Wegovy), Dulaglutide (Trulicity), Exenatide extended-release (Bydureon), Tirzepatide (Mounjaro, Zepbound) The once-weekly formulations generally offer greater convenience and may improve adherence